Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEAL: Ranibizumab for Diabetic Macular Edema
NCT00989989Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2009
- Primary completion
- Aug 2011
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of ranibizumab in diabetic macular edema (DME) (3 arms), sponsored by Novartis. Primary endpoint: Average Change From Baseline of Best-Corrected Visual Acuity at 12 months. Started Sep 2009; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT00989989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00989989.